WebMay 12, 2024 · There are currently no approved treatments for ADOA,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. “Our TANGO technology represents a unique, mutation-independent approach to treating the underlying cause of a variety of genetic diseases, particularly in the central nervous system and the eye. WebDec 14, 2024 · TANGO exploits unique, patented mechanisms for antisense-mediated modulation of splicing to prevent the synthesis of naturally occurring non-productive messenger RNA, or mRNA, and to increase the...
Stoke Therapeutics to Present at The Association for Research in …
WebJul 9, 2024 · Our approach, termed targeted augmentation of nuclear gene output (TANGO), exploits ASO-mediated modulation of naturally occurring non-productive AS events. We … WebMay 4, 2024 · TANGO (Targeted Augmentation of Nuclear Gene Output) is Stoke’s proprietary research platform. Stoke’s initial application for this technology are diseases in which one copy of a gene... stick route vs hitch route
Stoke Therapeutics: A Preclinical Biopharma With A ... - SeekingAlpha
WebJan 10, 2024 · About Stoke Therapeutics Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases … WebNov 21, 2024 · Headquartered in Boston, Stoke Therapeutics is a biotechnology company focused on upregulating protein expression with RNA-based medicines. Using a proprietary TANGO (Targeted Augmentation of... WebWho is Stoke Therapeutics Headquarters 45 Wiggins Ave, Bedford, Massachusetts, 01730, United States Phone Number (781) 430-8200 Website www.stoketherapeutics.com Revenue <$5M Stock Symbol STOK Industry Business Services General Business Services Stoke Therapeutics's Social Media Is this data correct? View contact profiles from Stoke … stick rpg 2 best paying job